The shrinking of the knowledge base – what is the impact of this on the speed and security of drug development?

02 February 2010
Download Type: Adobe PDF

Paul Branthwaite discusses the implication of reducing the Pharmaceutical industry knowledge base as a result of mergers, acquisitions and a drive to reduce cost base. He specificaly deals with the impact of these changes on the ability to produce innovative pharmaceuticals and the time required so to do.

We sit at the start of an R&D revolution.

Drug development is undergoing significant change to permanently re-shape its activities, with moves away from large budgets and research teams towards external resources. Because pricing pressures from patients, governments and insurance companies and rising cost hurdles to registering products, the drive to produce more effective, safer drugs, more cleverly and at lower development cost with less risk will continue.

Choose your knowledge partners with care!!

 

This download is categorized in:
Companies and People